Published in Anticancer Drugs on October 01, 1998
Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin. Mol Cancer Ther (2009) 0.79
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med (2000) 18.12
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
HEMOGLOBIN AND PLASMA PROTEIN : SIMULTANEOUS PRODUCTION DURING CONTINUED BLEEDING AS INFLUENCED BY AMINO ACIDS, PLASMA, HEMOGLOBIN, AND DIGESTS OF SERUM, HEMOGLOBIN, AND CASEIN. J Exp Med (1943) 4.18
Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res (1999) 4.17
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet (2000) 3.25
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
TEN AMINO ACIDS ESSENTIAL FOR PLASMA PROTEIN PRODUCTION EFFECTIVE ORALLY OR INTRAVENOUSLY. J Exp Med (1943) 2.91
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol (2000) 2.73
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature (1995) 2.54
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res (1983) 2.46
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol (1999) 2.29
Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (1998) 2.29
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol (2009) 2.21
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
CASEIN DIGESTS PARENTERALLY UTILIZED TO FORM BLOOD PLASMA PROTEIN. J Exp Med (1941) 2.18
The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem (1988) 2.15
Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol (2008) 2.12
Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol (1995) 2.08
Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res (2000) 2.06
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A (1989) 2.05
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol (1986) 1.94
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol (2006) 1.91
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol (1995) 1.85
The natural history of breast cancer patients with brain metastases. Cancer (1979) 1.82
Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res (1986) 1.82
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am (1998) 1.77
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst (1988) 1.73
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos (2000) 1.67
Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med (1994) 1.66
Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res (1980) 1.66
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J (2011) 1.63
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res (1979) 1.62
PLASMA SUBSTITUTES : HUMAN AND ANIMAL GLOBIN RELATED TO THE PRODUCTION OF HEMOGLOBIN AND PLASMA PROTEIN DOG HEMOGLOBIN UTILIZATION IMPROVED BY METHIONINE BUT NOT BY ISOLEUCINE. J Exp Med (1946) 1.61
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg (1999) 1.60
Spatial and temporal control of gene therapy using ionizing radiation. Nat Med (1995) 1.59
A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 1.59
Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med (1989) 1.59
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol (1997) 1.58
Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem (1980) 1.58
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol (1998) 1.58
Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer (1998) 1.57
Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer (1991) 1.57
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer (2001) 1.57
Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol (2010) 1.55
PERITONEAL ABSORPTION : RED CELLS LABELED BY RADIO-IRON HEMOGLOBIN MOVE PROMPTLY FROM PERITONEAL CAVITY INTO THE CIRCULATION. J Exp Med (1944) 1.55
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol (2007) 1.54
Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest (1988) 1.53
Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest (1996) 1.52
Tamoxifen-induced female androgenetic alopecia in a patient with breast cancer. Ann Intern Med (1997) 1.51
Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci U S A (1990) 1.50
Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther (1998) 1.50
Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest (1985) 1.49
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am (1999) 1.48
Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol (1998) 1.48
Isolated infraspinatus atrophy. A common cause of posterior shoulder pain and weakness in throwing athletes? Am J Sports Med (1989) 1.48
Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol (1995) 1.48
HEMOGLOBIN AND PLASMA PROTEIN PRODUCTION : VARIOUS PROTEINS, CONCENTRATES, AND DIGESTS INFLUENCE BLOOD PROTEIN PRODUCTION IN ANEMIA AND HYPOPROTEINEMIA. J Exp Med (1946) 1.46
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol (2000) 1.46
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol (2011) 1.45
Thermal injury and recovery of Bacillus subtilis. Appl Microbiol (1972) 1.45
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res (1997) 1.43
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol (2011) 1.42
The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg (1989) 1.41
Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. Cancer Res (1989) 1.41
Tamoxifen and contralateral breast cancer. J Am Coll Surg (1999) 1.41
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 1.41
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg (1998) 1.40
RAIDING OF BODY TISSUE PROTEIN TO FORM PLASMA PROTEIN AND HEMOGLOBIN : WHAT IS PREMORTAL RISE OF URINARY NITROGEN? J Exp Med (1947) 1.40
Discouraging news for high-dose chemotherapy in high-risk breast cancer. Lancet (1998) 1.40
Stopping a clinical trial very early because of toxicity: summarizing the evidence. Control Clin Trials (1993) 1.39
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol (1994) 1.39
Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys (1993) 1.38
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood (1997) 1.37
PLASMA PROTEIN AND HEMOGLOBIN PRODUCTION : DELETION OF INDIVIDUAL AMINO ACIDS FROM GROWTH MIXTURE OF TEN ESSENTIAL AMINO ACIDS. SIGNIFICANT CHANGES IN URINARY NITROGEN. J Exp Med (1947) 1.34
Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci U S A (1987) 1.34
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res (1988) 1.34
Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem (1990) 1.32
Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci U S A (1993) 1.32
A prospective study of the progression of rheumatoid arthritis of the cervical spine. J Bone Joint Surg Am (1981) 1.32
Clinical course of breast cancer patients with liver metastases. J Clin Oncol (1987) 1.32
Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer (1992) 1.31
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist (2001) 1.29
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol (2001) 1.28
Sequence studies of satellite tobacco necrosis virus RNA. Isolation and characterization of a 5'-terminal trinucleotide. J Mol Biol (1968) 1.28
Multimodal treatment of locoregionally advanced breast cancer. Cancer (1983) 1.26